



## Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

August 2, 2023

ALPHARETTA, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS<sup>®</sup>), announced that management will participate in the following investor conferences in August 2023:

Chardan Virtual Ophthalmology Summit  
Age-Related Macular Degeneration and Diabetes-Related Eye Diseases Series  
Fireside Chat (Available on Demand)

BTIG Virtual Biotechnology Conference  
Corporate Presentation and One-on-One Investor Meetings  
August 7, 2023 at 2:30 pm (Presentation)

H.C. Wainwright 3<sup>rd</sup> Annual Ophthalmology Virtual Conference  
Panel Discussion, Corporate Presentation and One-on-One Investor Meetings  
August 16, 2023 at 11:00 am ET (Panel)

A link to available live and archived webcasts may be accessed on the Clearside website under the Investors section: [Events and Presentations](#).

### About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS<sup>®</sup>). Clearside's SCS injection platform, utilizing the Company's patented SCS Microinjector<sup>®</sup>, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, [XIPERE<sup>®</sup> \(triamcinolone acetonide injectable suspension\)](#) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit [clearsidebio.com](http://clearsidebio.com).

Source: Clearside Biomedical, Inc.

Investor and Media Contacts: Jenny Kobin Remy Bernarda [ir@clearsidebio.com](mailto:ir@clearsidebio.com) (678) 430-8206